Heparin
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Heparin
- Heparin: From Anticoagulant Therapy to Thrombophilia due to Protein C Deficiency (Autosomal Recessive)
Heparin: From Anticoagulant Therapy to Thrombophilia due to Protein C Deficiency (Autosomal Recessive)
One-Sentence Summary
Heparin is an injectable anticoagulant that is widely marketed in the United States. The TxGNN model predicts it may be relevant for thrombophilia due to protein C deficiency, autosomal recessive, with a score of 99.29%. There are currently 0 clinical trials and 0 publications supporting this specific prediction, so it is a computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Thrombophilia due to protein C deficiency, autosomal recessive |
| TxGNN Prediction Score | 99.29% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (NDA and ANDA licenses combined) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the supplied record. Based on general pharmacology, heparin potentiates antithrombin and thereby inhibits thrombin and factor Xa. Its anticoagulant effect has been established in other thrombotic settings, and mechanistically it may be applicable to a hypercoagulable state.
Protein C deficiency is an inherited thrombophilia in which the natural anticoagulant pathway is impaired. This is a plausible conceptual link to an anticoagulant. Heparin may already be used as standard anticoagulation for acute thrombosis in this condition. The supplied data does not show this, and it should be checked against clinical guidelines before any repurposing claim is made.
The high TxGNN score is a computational signal. No trials, literature, or recorded original indication support it in this evidence pack.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The following are 5 of the 20 listed authorizations. All are injectable products. The record does not include approved indication text.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA090808 | Heparin Sodium | Injection, solution | Sagent Pharmaceuticals |
| NDA018916 | Heparin Sodium | Injection, solution | Hospira, Inc. |
| ANDA214839 | Heparin Sodium | Injection, solution | BE Pharmaceuticals Inc. |
| NDA019953 | Heparin Sodium in Sodium Chloride | Injection | B. Braun Medical Inc. |
| NDA017029 | Heparin Sodium | Injection, solution | Henry Schein, Inc. |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score and a plausible anticoagulant rationale. However, there are no clinical trials or publications for this indication, and no original indication or mechanism data is recorded. Evidence is at L5 and cannot support advancing.
To proceed, the following is needed:
- Package insert warnings and contraindications (blocking item for safety screening)
- Mechanism of action data, for example from DrugBank
- A guideline and literature check on current heparin use in protein C deficiency, to separate true repurposing from existing standard care
- Route and dosing compatibility assessment for this indication
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.